Aurinia Pharmaceuticals Nine-Month Net Income Rises 35% to $103.47 Million

Bitget2026/10/30 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aurinia Pharmaceuticals’ net income rose to $31.7 million for the three months ended September 30, 2026.
Total revenue climbed 14% year over year to $83.7 million for the same period.
Operating cash flow increased 46% year over year to $131.5 million for the nine months ended September 30, 2026.
Aurinia initiated the Phase 4 PRESERVE study investigating LUPKYNIS combined with biologic agents in patients with lupus nephritis.
The company raised its 2026 total revenue guidance to $325 million–$330 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261030369613) on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aurinia Pharmaceuticals Nine-Month Net Income Rises 35% to $103.47 Million

You may also like

Crypto prices